The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema.

Albert Joseph AugustinSilvia BoppMartin FechnerFrank G HolzDirk SandnerAndrea-M WinkgenRamin KhoramniaThomas NeuhannMarkus WarscherMartin S SpitzerWalter SekundoBerthold SeitzTobias DunckerChristian KsinsikHelmut Höh

Published in: European journal of ophthalmology (2021)

These long-term data suggest that the 0.2 μg/day FAc implant is effective in both vitrectomized and non-vitrectomized patients, with a manageable safety profile, and improved VA and reduced supplemental therapies for patients with a suboptimal response to first-line DME therapies. Clinicians may consider utilizing the FAc implant earlier in the DME disease process.

Keyphrases

soft tissue
palliative care
electronic health record
diabetic retinopathy
big data
type diabetes
machine learning
weight loss
data analysis
deep learning